Pharmaceuticals Search Engine [selected websites]

Wednesday, February 8, 2012

Bridge Bioresearch : Completion of Preclinical Trials of 2hydroxyoleic Acid - a Novel Treatment of Obesity

Bridge Bioresearch
LONDON, January 11, 2012 - Bridge Bioresearch PLC (BBR) announces that the company has completed the preclinical efficacy and safety trials of 2hydroxyoleic acid (2OHOA) a novel treatment of obesity and other metabolic disorders.

BBR has in- licensed 2OHOA from the University of the Balearic Islands (Spain) in 2006 and has continued research in animal models verifying the pharmacological properties as well as safety profile of the 2OHOA molecule. This is an important milestone for the further development of 2HOA and the move from pre-clinical to clinical development of the molecule as all the tests completed to-date have shown the molecule to be biologically active and safe in the standard animal models.

Søren Stenderup, CEO of BBR commented: "The successful completion of the pre-clinical programme is a significant milestone for this molecule. The fact that the product shows good biological activity and no observed toxicity gives us the confidence to commit time and resource to undertaking a full clinical development programme. The observation, in the animal models examined, that the product appears to improve other conditions associated with obesity such as hypertension and the onset of type 2 diabetes is an additional benefit that we will seek to quantify in the clinical trial programme as this will give the product benefits over other treatments for the growing problem of obesity."

About the 2hydroxyoleic acid molecule: 

2OHOA has a granted patent (PCT/ES02/00475) and the clinical development process as drug for the treatment of obesity has already been initiated following the encouraging results from the pre-clinical studies... Bridge Bioresearch's Press Release -